Economic burden and the cost-effectiveness of treatment of cardiovascular diseases in Africa

被引:65
|
作者
Gaziano, T. A. [1 ]
机构
[1] Brigham & Womens Hosp, Div Cardiovasc Med, Boston, MA 02115 USA
关键词
D O I
10.1136/hrt.2007.128785
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Cardiovascular disease is the leading cause of death in those over the age of 45 in Africa. The economic toll from cardiovascular diseases is equally devastating, leading to billions of dollars lost due to healthcare costs and reduced productivity from the disabling and fatal outcomes related to diabetes, hypertension, stroke, valvular heart disease, and heart failure. Much of it is preventable. With reasonable screening programmes and judicious use of scarce resources much of the suffering can be alleviated. This article reviews the economic burden attributable to cardiovascular disease in Africa and many of the potential cost-effective solutions to the large burden. It further outlines many of the areas where we know less and must focus our future research in trying to outline cost-effective solutions.
引用
收藏
页码:140 / 144
页数:5
相关论文
共 50 条
  • [31] Cost-Effectiveness of Cardiovascular Disease Spending
    Miller, George
    Cohen, Joshua T.
    Roehrig, Charles
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2012, 60 (20) : 2123 - 2124
  • [32] Cost-effectiveness Considerations of Cardiovascular Therapeutics
    Keech, Anthony
    Horowitz, John D.
    [J]. HEART LUNG AND CIRCULATION, 2009, 18 (02): : 118 - 122
  • [33] Population Strategies to Decrease Sodium Intake and the Burden of Cardiovascular Disease A Cost-Effectiveness Analysis
    Smith-Spangler, Crystal M.
    Juusola, Jessie L.
    Enns, Eva A.
    Owens, Douglas K.
    Garber, Alan M.
    [J]. ANNALS OF INTERNAL MEDICINE, 2010, 152 (08) : 481 - U21
  • [34] COST-EFFECTIVENESS OF RARE DISEASES IN SPAIN
    Pomares, E.
    Uria, E.
    Martinez-Rodriguez, I
    Cuesta, M.
    [J]. VALUE IN HEALTH, 2018, 21 : S454 - S454
  • [35] Cost-effectiveness analysis in infectious diseases
    Paul, M.
    [J]. CLINICAL MICROBIOLOGY AND INFECTION, 2010, 16 (12) : 1705 - 1706
  • [36] Cost-Effectiveness of Biologics for Allergic Diseases
    Wu, Ann Chen
    Fuhlbrigge, Anne L.
    Robayo, Maria Acosta
    Shaker, Marcus
    [J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE, 2021, 9 (03): : 1107 - +
  • [37] The Economic Burden of Somatization Syndromes: A Systematic Review of Cost-Of-Illness Studies and Cost-Effectiveness Analyses
    Konnopka, Alexander
    Schaefert, Rainer
    Heinrich, Sven
    Leicht, Hanna
    Kaufmann, Claudia
    Luppa, Melanie
    Herzog, Wolfgang
    Koenig, Hans-Helmut
    [J]. JOURNAL OF MENTAL HEALTH POLICY AND ECONOMICS, 2011, 14 : S16 - S17
  • [38] A systematic review on the economic burden of interstitial lung disease and the cost-effectiveness of current therapies
    Alyson W. Wong
    John Koo
    Christopher J. Ryerson
    Mohsen Sadatsafavi
    Wenjia Chen
    [J]. BMC Pulmonary Medicine, 22
  • [39] Societal economic burden of multiple sclerosis and cost-effectiveness of disease-modifying therapies
    Simoens, Steven
    [J]. FRONTIERS IN NEUROLOGY, 2022, 13
  • [40] The economic burden of Lyme disease and the cost-effectiveness of Lyme disease interventions: A scoping review
    Mac, Stephen
    da Silva, Sara R.
    Sander, Beate
    [J]. PLOS ONE, 2019, 14 (01):